Tencent, Charles River Laboratories and National Resilience all backed the stem cell technology developer’s series B round.

Bit.bio, a UK-based developer of stem cell programming technology, completed a $103m series B round today featuring internet group Tencent, drug development services profider Charles River Laboratories and pharmaceutical manufacturer National Resilience.

Puhua Capital, Arch Ventures, Foresite Capital and Metaplanet also contributed to the round, which took company’s total funding to approximately $153m.

Founded in 2016 as Elpis Biomed and spun out of University of Cambridge, Bit.bio has built a technology platform that reprograms stem cells for a variety of…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn